Agilent Technologies, Inc. (A) EV/EBITDA Ratio: 20.92x
Is Agilent Technologies, Inc.’s EV/EBITDA ratio high or low?
Agilent Technologies, Inc.'s EV/EBITDA ratio of 20.92x is in line with its 5-year average of 23.11x, near the low end of its 5-year range (16.58x–37.96x).
The EV/EBITDA ratio for Agilent Technologies, Inc. (A) is 20.92x as of Wednesday, June 10, 2026. It is below its 12-month average by 0.94% (21.12x).
A EV/EBITDA Ratio Chart
A Average EV/EBITDA Ratio Chart
A Current vs Average EV/EBITDA Ratio Chart
A EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
20.92x
EV/EBITDA RATIO AVG TTM
21.12x
EV/EBITDA RATIO AVG 3Y
21.69x
EV/EBITDA RATIO AVG 5Y
23.11x
EV/EBITDA RATIO AVG 10Y
22.16x
EV/EBITDA RATIO AVG 15Y
19.36x
EV/EBITDA RATIO AVG 20Y
18.01x
CURRENT VS TTM AVG
-0.94%
CURRENT VS 3Y AVG
-3.57%
CURRENT VS 5Y AVG
-9.49%
CURRENT VS 10Y AVG
-5.59%
CURRENT VS 15Y AVG
+8.06%
CURRENT VS 20Y AVG
+16.17%
A Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | $37.17B | 20.92x | 21.12x | 21.69x | 23.11x |
| Zoetis Inc. (ZTS) | $34.20B | 10.33x | 15.67x | 20.68x | 23.76x |
| Centene Corporation (CNC) | $31.94B | N/A | 4.99x | 7.28x | 9.49x |
| Medline Inc. (MDLN) | $30.90B | 13.75x | 15.00x | 15.00x | 15.00x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 8.90x | 13.19x | 14.98x | 17.09x |
| Humana Inc. (HUM) | $43.78B | 18.61x | 11.68x | 11.33x | 12.36x |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 30.48x | 35.75x | 34.46x | 38.26x |
| DexCom, Inc. (DXCM) | $29.24B | 23.24x | 28.10x | 43.48x | 70.03x |
| Biogen Inc. (BIIB) | $29.00B | 11.60x | 8.56x | 11.16x | 12.22x |
| Veeva Systems Inc. (VEEV) | $26.73B | 25.37x | 43.29x | 56.90x | 62.37x |
EV/EBITDA vs. its own history
At 20.9, EV/EBITDA is richer than usual — richer than 70% of its 20-year range.
20-year low
3.4
median
18.5
20-year high
38.0
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
Agilent Technologies, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Agilent Technologies, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
- The EV/EBITDA ratio for A stock is 20.92x.
- Is Agilent Technologies, Inc.'s EV/EBITDA ratio high or low?
- Agilent Technologies, Inc.'s EV/EBITDA ratio of 20.92x is in line with its 5-year average of 23.11x, near the low end of its 5-year range (16.58x–37.96x).
- What is the TTM average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
- The TTM average EV/EBITDA ratio for A stock is 21.12x.
- What is the 3Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
- The 3Y average EV/EBITDA ratio for A stock is 21.69x.
- What is the 5Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
- The 5Y average EV/EBITDA ratio for A stock is 23.11x.
- What is the 10Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
- The 10Y average EV/EBITDA ratio for A stock is 22.16x.
- What is the 15Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
- The 15Y average EV/EBITDA ratio for A stock is 19.36x.
- What is the 20Y average EV/EBITDA ratio for Agilent Technologies, Inc. (A)?
- The 20Y average EV/EBITDA ratio for A stock is 18.01x.
Agilent Technologies, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-10 | 20.92x |
| 2026-06-09 | 21.51x |
| 2026-06-08 | 21.08x |
| 2026-06-05 | 21.50x |
| 2026-06-04 | 21.95x |
| 2026-06-03 | 21.80x |
| 2026-06-02 | 21.44x |
| 2026-06-01 | 21.58x |
| 2026-05-29 | 21.98x |
| 2026-05-28 | 21.95x |
| 2026-05-27 | 18.91x |
| 2026-05-26 | 18.79x |
| 2026-05-22 | 18.77x |
| 2026-05-21 | 18.75x |
| 2026-05-20 | 18.59x |
| 2026-05-19 | 18.09x |
| 2026-05-18 | 18.33x |
| 2026-05-15 | 18.27x |
| 2026-05-14 | 18.51x |
| 2026-05-13 | 18.43x |
| 2026-05-12 | 18.45x |
| 2026-05-11 | 18.23x |
| 2026-05-08 | 18.88x |
| 2026-05-07 | 19.35x |
| 2026-05-06 | 19.20x |
| 2026-05-05 | 19.17x |
| 2026-05-04 | 18.34x |
| 2026-05-01 | 18.71x |
| 2026-04-30 | 18.87x |
| 2026-04-29 | 18.20x |
| 2026-04-28 | 18.76x |
| 2026-04-27 | 18.88x |
| 2026-04-24 | 18.87x |
| 2026-04-23 | 18.69x |
| 2026-04-22 | 19.63x |
| 2026-04-21 | 19.88x |
| 2026-04-20 | 19.71x |
| 2026-04-17 | 19.85x |
| 2026-04-16 | 19.29x |
| 2026-04-15 | 19.52x |
| 2026-04-14 | 19.62x |
| 2026-04-13 | 19.17x |
| 2026-04-10 | 18.79x |
| 2026-04-09 | 18.84x |
| 2026-04-08 | 19.08x |
| 2026-04-07 | 18.61x |
| 2026-04-06 | 18.76x |
| 2026-04-02 | 18.86x |
| 2026-04-01 | 18.71x |
| 2026-03-31 | 18.62x |
| 2026-03-30 | 18.32x |
| 2026-03-27 | 18.04x |
| 2026-03-26 | 18.54x |
| 2026-03-25 | 18.47x |
| 2026-03-24 | 18.66x |
| 2026-03-23 | 18.32x |
| 2026-03-20 | 18.20x |
| 2026-03-19 | 18.27x |
| 2026-03-18 | 18.24x |
| 2026-03-17 | 18.43x |
| 2026-03-16 | 18.29x |
| 2026-03-13 | 18.24x |
| 2026-03-12 | 18.26x |
| 2026-03-11 | 18.85x |
| 2026-03-10 | 18.85x |
| 2026-03-09 | 19.04x |
| 2026-03-06 | 18.79x |
| 2026-03-05 | 19.26x |
| 2026-03-04 | 19.64x |
| 2026-03-03 | 19.41x |
| 2026-03-02 | 19.14x |
| 2026-02-27 | 19.64x |
| 2026-02-26 | 19.58x |
| 2026-02-25 | 20.16x |
| 2026-02-24 | 20.11x |
| 2026-02-23 | 20.08x |
| 2026-02-20 | 19.87x |
| 2026-02-19 | 20.41x |
| 2026-02-18 | 20.50x |
| 2026-02-17 | 20.02x |
| 2026-02-13 | 20.32x |
| 2026-02-12 | 20.18x |
| 2026-02-11 | 20.80x |
| 2026-02-10 | 20.82x |
| 2026-02-09 | 20.59x |
| 2026-02-06 | 20.91x |
| 2026-02-05 | 20.92x |
| 2026-02-04 | 21.43x |
| 2026-02-03 | 21.30x |
| 2026-02-02 | 21.81x |
| 2026-01-30 | 21.57x |
| 2026-01-29 | 21.48x |
| 2026-01-28 | 21.57x |
| 2026-01-27 | 21.89x |
| 2026-01-26 | 21.85x |
| 2026-01-23 | 21.75x |
| 2026-01-22 | 22.31x |
| 2026-01-21 | 22.48x |
| 2026-01-20 | 21.88x |
| 2026-01-16 | 22.46x |
| 2026-01-15 | 23.27x |
| 2026-01-14 | 23.44x |
| 2026-01-13 | 23.50x |
| 2026-01-12 | 23.76x |
| 2026-01-09 | 23.84x |
| 2026-01-08 | 23.41x |
| 2026-01-07 | 23.73x |
| 2026-01-06 | 23.70x |
| 2026-01-05 | 22.97x |
| 2026-01-02 | 22.20x |
| 2025-12-31 | 21.91x |
| 2025-12-30 | 22.15x |
| 2025-12-29 | 22.20x |
| 2025-12-26 | 22.27x |
| 2025-12-24 | 22.26x |
| 2025-12-23 | 22.27x |
| 2025-12-22 | 22.29x |
| 2025-12-19 | 22.09x |
| 2025-12-18 | 22.75x |
| 2025-12-17 | 22.72x |
| 2025-12-16 | 23.12x |
| 2025-12-15 | 23.34x |
| 2025-12-12 | 23.20x |
| 2025-12-11 | 23.70x |
| 2025-12-10 | 23.80x |
| 2025-12-09 | 23.35x |
| 2025-12-08 | 23.63x |
| 2025-12-05 | 24.12x |
| 2025-12-04 | 24.57x |
| 2025-12-03 | 24.72x |
| 2025-12-02 | 24.64x |
| 2025-12-01 | 24.85x |
| 2025-11-28 | 25.39x |
| 2025-11-26 | 25.53x |
| 2025-11-25 | 25.97x |
| 2025-11-24 | 25.40x |
| 2025-11-21 | 25.03x |
| 2025-11-20 | 24.05x |
| 2025-11-19 | 23.94x |
| 2025-11-18 | 23.86x |
| 2025-11-17 | 23.96x |
| 2025-11-14 | 24.33x |
| 2025-11-13 | 24.34x |
| 2025-11-12 | 25.07x |
| 2025-11-11 | 24.74x |
| 2025-11-10 | 24.26x |
| 2025-11-07 | 24.32x |
| 2025-11-06 | 24.43x |
| 2025-11-05 | 24.32x |
| 2025-11-04 | 24.21x |
| 2025-11-03 | 23.99x |
| 2025-10-31 | 24.26x |
| 2025-10-30 | 23.78x |
| 2025-10-29 | 23.75x |
| 2025-10-28 | 24.17x |
| 2025-10-27 | 24.29x |
| 2025-10-24 | 24.52x |
| 2025-10-23 | 24.43x |
| 2025-10-22 | 24.18x |
| 2025-10-21 | 24.15x |
| 2025-10-20 | 23.72x |
| 2025-10-17 | 23.55x |
| 2025-10-16 | 23.42x |
| 2025-10-15 | 23.19x |
| 2025-10-14 | 22.94x |
| 2025-10-13 | 22.97x |
| 2025-10-10 | 22.71x |
| 2025-10-09 | 23.26x |
| 2025-10-08 | 23.37x |
| 2025-10-07 | 23.02x |
| 2025-10-06 | 23.50x |
| 2025-10-03 | 23.51x |
| 2025-10-02 | 23.04x |
| 2025-10-01 | 23.02x |
| 2025-09-30 | 21.40x |
| 2025-09-29 | 20.67x |
| 2025-09-26 | 20.61x |
| 2025-09-25 | 20.37x |
| 2025-09-24 | 20.77x |
| 2025-09-23 | 21.02x |
| 2025-09-22 | 21.08x |
| 2025-09-19 | 21.08x |
| 2025-09-18 | 21.28x |
| 2025-09-17 | 21.14x |
| 2025-09-16 | 21.21x |
| 2025-09-15 | 20.97x |
| 2025-09-12 | 20.59x |
| 2025-09-11 | 21.14x |
| 2025-09-10 | 20.73x |
| 2025-09-09 | 21.07x |
| 2025-09-08 | 21.36x |
| 2025-09-05 | 21.46x |
| 2025-09-04 | 21.42x |
| 2025-09-03 | 20.90x |
| 2025-09-02 | 20.90x |
| 2025-08-29 | 20.97x |
| 2025-08-28 | 21.39x |
| 2025-08-27 | 20.37x |
| 2025-08-26 | 20.31x |
| 2025-08-25 | 20.45x |
| 2025-08-22 | 20.85x |
| 2025-08-21 | 20.12x |
| 2025-08-20 | 20.44x |
| 2025-08-19 | 20.60x |
| 2025-08-18 | 20.29x |
| 2025-08-15 | 20.46x |
| 2025-08-14 | 20.40x |
| 2025-08-13 | 20.63x |
| 2025-08-12 | 20.15x |
| 2025-08-11 | 19.63x |
| 2025-08-08 | 19.71x |
| 2025-08-07 | 19.61x |
| 2025-08-06 | 19.49x |
| 2025-08-05 | 19.76x |
| 2025-08-04 | 19.75x |
| 2025-08-01 | 19.53x |
| 2025-07-31 | 19.74x |
| 2025-07-30 | 20.27x |
| 2025-07-29 | 20.56x |
| 2025-07-28 | 20.51x |
| 2025-07-25 | 20.61x |
| 2025-07-24 | 20.64x |
| 2025-07-23 | 20.50x |
| 2025-07-22 | 19.97x |
| 2025-07-21 | 19.30x |
| 2025-07-18 | 19.61x |
| 2025-07-17 | 20.00x |
| 2025-07-16 | 19.52x |
| 2025-07-15 | 19.44x |
| 2025-07-14 | 20.60x |
| 2025-07-11 | 21.12x |
| 2025-07-10 | 21.26x |
| 2025-07-09 | 20.80x |
| 2025-07-08 | 20.75x |
| 2025-07-07 | 20.46x |
| 2025-07-03 | 20.81x |
| 2025-07-02 | 20.69x |
| 2025-07-01 | 20.66x |
| 2025-06-30 | 20.26x |
| 2025-06-27 | 20.45x |
| 2025-06-26 | 20.49x |
| 2025-06-25 | 20.36x |
| 2025-06-24 | 20.20x |
| 2025-06-23 | 19.96x |
| 2025-06-20 | 19.87x |
| 2025-06-18 | 19.86x |
| 2025-06-17 | 19.95x |
| 2025-06-16 | 20.43x |
| 2025-06-13 | 20.11x |
| 2025-06-12 | 20.41x |
| 2025-06-11 | 20.54x |
| 2025-06-10 | 20.67x |
| 2025-06-09 | 20.06x |
| 2025-06-06 | 19.90x |
| 2025-06-05 | 19.60x |
| 2025-06-04 | 19.77x |
| 2025-06-03 | 19.41x |
| 2025-06-02 | 19.13x |
| 2025-05-30 | 19.28x |
| 2025-05-29 | 18.77x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell